3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Breast Neoplasms
3
Stomach Neoplasms
1
Psychological Well-Being
1
Psoriasis
1
Peripheral Nervous System Diseases
1
Osteoarthritis
1
Neoplasms
1
Multiple Myeloma
1
Motor Activity
1
Lung Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cardiovascular Diseases
1
Autoimmune Diseases
1
Arthritis, Rheumatoid
1
Arthralgia
1
Interventions
Oxaliplatin
64
pembrolizumab
48
Fluorouracil
44
Capecitabine
38
Nivolumab
33
Leucovorin
32
Paclitaxel
28
Trastuzumab
19
Docetaxel
18
Cisplatin
18
S 1 (combination)
16
Bevacizumab
15
Ramucirumab
13
Irinotecan
13
Drug Therapy
13
tislelizumab
12
Cyclophosphamide
12
fludarabine
10
Carboplatin
10
Radiotherapy
9
Magnetic Resonance Spectroscopy
9
trastuzumab deruxtecan
8
sintilimab
8
Specimen Handling
8
Biopsy
8
atezolizumab
7
Surgical Procedures, Operative
7
Gemcitabine
7
zolbetuximab
6
durvalumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Fish Oils
×
1 year
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled